Phase 2 Study Initiated for HIF-2α Agent in Relapsed/Refractory RCC
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
These are the first set of recommendations on the use of tumor multigene NGS profiling in daily practice issued by a scientific society for patients with metastatic cancer.
SEER analysis reveals age, Ann Arbor stage, and chemotherapy as critical factors affecting prognosis in patients with primary cardiac lymphoma.
The use of telemedicine has been surging since the onset of coronavirus disease 2019 (COVID-19), with millions of Americans now using this medium for connecting with their clinicians, according to a report that appeared in Kaiser Health News.1 The increase in use of this modality can be attributed to fears of contracting COVID-19, social distancing…
Pemigatinib, a small molecule kinase inhibitor, selectively targets FGFR isoforms 1, 2 and 3, which, in preclinical studies, has resulted in anti-tumor activity in cells with FGFR alterations.
Optimal combinations of MEK, ROS1 inhibitors should be explored.
A study found that patients with more advanced-stage upper tract urothelial carcinoma had a higher prevalence of lymph node metastasis.
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
Chart with medications used to treat neuropathic pain, including diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia.
Adult doses for migraine and headache treatments including barbiturates, ergot alkaloids, and NSAIDs.